JPRN-jRCT2061210033进行中（未招募）2 期
A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma
Hoki Toshifumi0 个研究点目标入组 6 人开始时间: 2021年9月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Has an hepatocellular carcinoma (HCC) diagnosis confirmed by radiology, histology, or cytology (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible)
- •- Has Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment approach
- •- Has a Child-Pugh class A liver score within 7 days prior to first dose of study intervention
- •- Has a predicted life expectancy of >3 months
- •- Has at least 1 measurable HCC lesion based on RECIST 1.1, confirmed by BICR
- •- Has an Eastern Cooperative Oncology Group Performance Score (ECOG PS) of 0 to 1 within 7 days prior to first dose of study intervention
- •- Participants with controlled hepatitis B will be eligible as long as they meet the following criteria: antiviral therapy for Hepatitis B virus (HBV) must be given for at least 4 weeks and HBV viral load must be less than 500 IU/mL prior to first dose of study drug
- •- Has adequately controlled blood pressure with or without antihypertensive medications
- •- Has adequate organ function
排除标准
- •- Has had esophageal or gastric variceal bleeding within the last 6 months.
- •- Has bleeding or thrombotic disorders or use of factor X inhibitors or anticoagulants requiring therapeutic international normalized ratio (INR) monitoring, e.g., warfarin or similar agents
- •- Has clinically apparent ascites on physical examination
- •- Has inferior vena cava or cardiac involvement of HCC based on imaging
- •- Has had clinically diagnosed hepatic encephalopathy in the last 6 months unresponsive to therapy
- •- Has medical contraindications that preclude all forms of contrast-enhanced imaging (computed tomography [CT] or magnetic resonance imaging [MRI])
- •- Has gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
- •- Has a preexisting Grade >=3 gastrointestinal or non-gastrointestinal fistula
- •- Has clinically active hemoptysis (bright red blood of a least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug
- •- Has clinically significant cardiovascular impairment within 12 months of the first dose of study intervention, including New York Heart Association (NYHA) Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability
- •- Has had major surgery to the liver within 4 weeks prior to the first dose of study intervention
- •- Has had a minor surgery (i.e., simple excision) within 7 days prior to the first dose of study intervention (Cycle 1 Day 1)
- •- Has serious nonhealing wound, ulcer, or bone fracture
- •- Has received any systemic chemotherapy, including anti- vascular endothelial growth factor (VEGF) therapy, or any systemic investigational anticancer agents for treatment of HCC
- •- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
- •- Has received locoregional therapy to liver within 4 weeks prior to the first dose of study intervention
- •- Has received prior radiotherapy to a non-liver region within 2 weeks of start of study intervention
- •- Has received a live or live-attenuated vaccine within 30 days before the first dose of study drug
- •- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
- •- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention
- •- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- •- Has a known history of, or any evidence of, central nervous system (CNS) metastases and/or carcinomatous meningitis as assessed by local site investigator
- •- Has severe hypersensitivity (>=Grade 3) to study intervention and/or any of their excipients
- •- Has an active autoimmune disease that has required systemic treatment in past 2 years
- •- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- •- Has an active infection requiring systemic therapy, with the exception of HBV or Hepatitis C virus (HCV)
- •- Has a known history of human immunodeficiency virus (HIV) infection
- •- Has dual active HBV infection (HBsAg (+) and /or detectable H
研究者
相似试验
招募中
1 期
Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaHepatocellular carcinomaCTIS2023-505698-34-00Merck Sharp & Dohme LLC102
进行中（未招募）
1 期
Phase 2 Study of MK 1308A (Coformulated MK 1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaAdvanced hepatocellular carcinoma without any prior systemic treatmentMedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004490-52-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.110
进行中（未招募）
1 期
Phase 2 Study of MK 1308A (Coformulated MK 1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaEUCTR2020-004490-52-PLMerck Sharp & Dohme LLC110
进行中（未招募）
不适用
A phase II, multicentre, clinical study evaluating the safety and efficacy of Treosulfan-based conditioning of allogenic transplantation of haemopoietic stem-cells in patients affected by Thalassemia Major - NDEUCTR2005-005913-40-ITOSPEDALE POLICLINICO S. MATTEO10
未知
2 期
A Phase II, Multicenter, Clinical Trial to Evaluate The Efficacy and Safety of Bevacizumab in Recurrent Malignant GliomaMalignant gliomaJPRN-jRCT2080220811Chugai Pharmaceutical Co., Ltd.31